Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

ries of studies was conducted to validate this approach.

-- Relative bioavailability was assessed in 40 patients randomized to naltrexone SR 40mg or naltrexone immediate release (IR) 36mg in a single dose, crossover PK assessment. Analyses revealed that, on a dose-normalized basis, naltrexone SR was associated with a 43.3% lower peak concentration but a comparable exposure or area-under-the-curve (AUC) to the IR formulation. The Tmax or time to peak concentration was approximately 36 minutes slower for naltrexone SR compared to naltrexone IR.

-- Preliminary evidence for improved tolerability with naltrexone SR came from a trial utilizing a multiple dose, parallel design in 60 healthy volunteers randomized to either naltrexone SR 37.5mg / bupropion SR 270mg or naltrexone IR 36mg / bupropion SR 270mg. Patients were treated for up to 14 days. Naltrexone SR / bupropion SR patients spontaneously reported fewer GI adverse events (10.3% vs. 16.7%) or CNS adverse events (10.3% vs. 23.3%). GI event severity was also subjectively lowered with the naltrexone SR formulation.

-- In a preliminary effort to evaluate apparent improvements in tolerability associated with naltrexone SR, pooled 24 week data from the Phase 2 NB-201 Contrave trial (N=212) with naltrexone IR was compared with the 24 week blinded data from a series of four Phase 3 Contrave trials (N=3,943 evaluable patients), all employing naltrexone SR. These Phase 3 trials all have varying designs, doses and patient populations; the discontinuation due to adverse event rates associated with them ranged from 13.8% to 22.8%. However, compared to the Phase 2 trial experience, lower rates of nausea were evident across the four pooled Phase 3 trials. In study NB-301 (N=1,689 evaluable patients), the trial with dosing most similar to the Phase 2 NB-201 trial, nausea, headache, or dizziness were all less frequent than in the prior Phase 2 trial, as was the overall rate of early discontinuation due to any a
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... product to receive formal designation as a "Promising Innovative ... Scheme" (EAMS) launched in the UK in April 2014. ... process for early access approval under the EAMS.  ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5
(Date:9/16/2014)... 2014 Marybeth Cale, owner of Cale ... of Manhattan in the small village of Rhinebeck, New York, ... business. Cale, a mompreneur, has expanded the business to incorporate ... people to maximize potential. Those services will include group trainings ... one-on-one life coaching for clients all over the country. ...
(Date:9/16/2014)... 2014 Operation Smile was founded “on the ... a facial deformity.” To spread their message and mission, the ... at the Beverly Wilshire Hotel in Beverly Hills, California. The ... whose lives have been forever transformed by the efforts of ... with Operation Smile,” said Lynda Erkiletian, Executive Director of The ...
(Date:9/16/2014)... 2014 On Friday, September 12, ... product extensions, an accompanying mobile application, the grand-opening ... tools for their sales force, and their sponsorship ... 5th annual national convention, Rise to Enterprise 2014 ... the Hyatt Regency Orange County was treated to ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... The Road , Free Education Forum for PH Patients and ... Pulmonary Hypertension Association – the country’s leading pulmonary hypertension ... pulmonary hypertension (PH) – a disease of the lungs that ... right heart failure. Without treatment, mean survivability is only 2.8 ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, ... spot human papillomavirus (HPV), which is linked to the risk ... shows that testing urine for HPV has good accuracy when ... said lead researcher Dr. Neha Pathak. She is a resident ... University of London, England. The test could be done ...
Breaking Medicine News(10 mins):Health News:Mompreneur Marybeth Cale of Cale Communications Announces Launch Of Life Coaching And Workshop Business 2Health News:James & Paula Coburn Foundation to Host the 2014 Smile Gala, Presented by Operation Smile 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 3Health News:New Products Announced at Jusuru International’s R2E14 National Convention 4Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Urine Test for HPV Works Well, Analysis Finds 2
... driving challenges this time of year, safety group says ... brings plenty of road hazards and challenges: wet leaves, lumbering ... year, September had the second-highest number of deaths per mile ... per 100 million vehicle miles, according to the National Safety ...
... ... year, 35 to 50 million Americans become infected with the flu (influenza). On average, the ... TX is taking steps to combat these preventable deaths by offering free flu shots . ... Plano, TX (Vocus) September 12, 2009 ...
... ... Pappagallo, MD, Present Partnering Primary Care Physicians with Pain Specialists , ... Las Vegas, NV (PRWEB) September 12, 2009 -- PAINWeek® ... CPE, and Dr. Marco Pappagallo, MD, teaching a Master Class that addressed the need for ...
... , , , ... leading provider of kidney care services for those diagnosed with chronic kidney ... series of 5K events raising funds and awareness of CKD across the ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) , , ...
... The Johns Hopkins Bloomberg School of Public Health has ... Research Program (OETRP) of the U.S. Department of Defense ... Bloomberg School will serve as the coordinating center for ... civilian trauma centers working together with several major military ...
... CHICAGO, Sept. 11 Schofield Media Group has promoted Brian ... U.S. and European operations consisting of five divisions and more than ... in 2006 as executive president, and in 2008 was made group ... made and continues to make a great contribution to the company," ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Need for Pain and Palliative Care Mentorship Addressed at PAINweek 2009 2Health News:DaVita Launches Nationwide Series of Kidney Awareness Run/Walks 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: